Welcome to European Tribune. It's gone a bit quiet around here these days, but it's still going.
Novavax seeks Covid-19 vaccine use in India ahead of US
The Novavax two-dose shot is made with lab-grown copies of the spike protein that coats the coronavirus. That's ["]very different["] than other widely used [mRNA] vaccines that deliver genetic instructions for the body to make its own spike protein.
In June [2021], Novavax announced the vaccine had proved about 90% effective against symptomatic Covid-19 in a study Phase III clinical trial of nearly 30,000 people in the U.S. and Mexico [and UK]. It also worked against variants circulating in those countries at the time. Side effects were mostly mild.
The Gaithersburg [Montgomery County], Maryland, company said it was on track to produce up to 100 million doses a month by the end of the third quarter and 150 million doses a month by year's end.
archived Tue Mar 3rd, 2020 "Johnson & Johnson [Janssen], Regeneron Pharmaceuticals Inc., Pfizer Inc. [BioNTech], Sanofi, GlaxoSmithKline PLC, Gilead Sciences Inc., Novavax Inc., Inovio Pharmaceuticals Inc., CureVac AG and Moderna Inc."
by Cat on Fri Aug 6th, 2021 at 04:04:35 PM EST
[ Parent ]

Others have rated this comment as follows:


Occasional Series